BI 1323495

BI 1323495 is a small molecule inhibitor of neutrophil elastase (also known as leukocyte elastase or ELA2), developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis. The drug acts as an anti-inflammatory agent, targeting neutrophil-driven inflammation in the airways by inhibiting the activity of neutrophil elastase, an enzyme implicated in tissue damage and airway remodeling in these respiratory diseases. Clinical development has included phase I trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with non-cystic fibrosis bronchiectasis[1][3][4][5].